Cannabis Medicine for Back Pain Aims to Displace Opioids

A cannabis-derived drug for lower back pain will soon go on sale in Germany and Austria in what its developer views as a dry ...

Signs of depression in men: Why it often goes unrecognized

Doctronic reports that men often show depression through anger, irritability, and risk-taking, leading to misdiagnosis and ...
MSN on MSN

Gene therapy treatment for sickle cell disease changes lives in St. Louis

A cutting-edge procedure for treating sickle cell disease is changing lives in the St. Louis area, where an estimated 1,200 ...

What drives lower-back nerve pain? Genetic clues could reshape stenosis care

An international research team has identified dozens of new genetic risk factors linked to lumbar spinal stenosis, a common ...
Targeted Oncology

Rapid Disease Control Drives Frontline Choices in Metastatic ccRCC

Treatment selection for newly diagnosed metastatic clear cell renal cell carcinoma (ccRCC) continues to evolve as clinicians ...

Perthshire gran celebrates after blood cancer drug given green light by NHS

Anne Head has described the approval of the pioneering new drug for people with the incurable blood cancer myeloma, as ...

KTPH surgeons develop new surgical approach to treat frequent shoulder dislocation

Discover KTPH's innovative keyhole surgery technique for shoulder dislocation, offering faster recovery and improved outcomes ...

Pain relief expert offers steps to finally end your chronic pain

Doctor urges people to address the root causes of pain. Healing can begin with better sleep, hormonal and immune system ...

The Inside Story Of The World’s First Cannabis-Based Painkiller

Now that Vertanical’s Exilby has been approved in Germany to treat chronic pain, Clemens Fischer, the pharma billionaire ...
Hawai‘i Public Radio

More Americans survive cancer. But the psychological impacts can persist for years

Due to advancements in treatment and screening, more Americans are surviving cancer. But many are left with lingering mental ...

Exilby® Receives First European Marketing Authorization as VERTANICAL Prepares UK Submission for its First-in-Class Non-Opioid Treatment for Chronic Low Back Pain

VERTANICAL today announced that Exilby® (VER-01) has received marketing authorization in Germany for the treatment of chronic low back pain with a radicular (neuropathic) component.

VERTANICAL Receives First European Marketing Authorization for Exilby® as a First-in-Class Non-Opioid Treatment for Chronic Low Back Pain - Pivotal U.S. Phase 3 trial underway

VERTANICAL today announced that Exilby® (VER-01) has received marketing authorization in Germany for the treatment of chronic low back pain with a radicular (neuropathic) component. The authorization ...